

Q5  
Q6  
13. A method as claimed in claim 12 wherein GPE is administered to protect non-dopaminergic neurons against death.

Q7  
14. A method as claimed in claim 12 wherein GPE is administered to protect glial cells against death.

15. A method as claimed in claim 13 wherein the dosage range of GPE administered is from about 1 $\mu$ g to about 1000mg of GPE per kg of body weight of the mammal.

16. A method as claimed in claim 14 wherein the dosage range of GPE administered is from about 1 $\mu$ g to about 1000mg of GPE per kg of body weight of the mammal.

17. A method as claimed in claim 12, further comprising applying an electrophoretic procedure in aid of said administration of GPE.

18. The method of claim 11, wherein said peptide is administered via maternal circulation.

19. A method as claimed in claim 12 in which a neuroprotective amount of GPE is administered prior to an event considered likely to lead to an injury to glial cells or non-dopaminergic neural cells.

20. The method of claim 19, wherein said event comprises cardiac surgery.

21. The method of claim 19, wherein said event comprises brain surgery.

22. The method of claim 19, wherein said event comprises parturition.

*Art A'*  
23. The method of claim 22, wherein said peptide is administered via maternal circulation.

24. A method as claimed in claim 19, wherein said event is considered likely to lead to an injury to glial cells.

25. A method as claimed in claim 12 in which GPE is administered subsequent to injury or disease affecting glial or non-dopaminergic neural cells but prior to death of said cells.

26. A method as claimed in claim 25, wherein said injury or disease affects non-dopaminergic neural cells.

27. A method as claimed in claim 25, wherein said injury or disease affects glial cells.

28. A method as claimed in claim 25, wherein said GPE is administered to protect glial or non-dopaminergic neural cells against death through injury, and wherein said GPE is administered for up to 100 hours subsequent to said injury.

29. A method as claimed in claim 28 in which GPE is administered from 0.5 to 8 hours subsequent to said injury.

30. A method as claimed in claim 12 in which GPE is administered directly to where the cell bodies of glial cells or non-dopaminergic neural cells to be protected are located.

31. A method of claim 30, wherein said cells to be protected comprise glial cells.

*SUB CL*  
32. A method as claimed in claim 30 wherein GPE is administered directly to the brain or cerebrospinal fluid by cerebro-ventricular injection, by injection into the cerebral